Shares across the biopharmaceutical sector in Hong Kong moved sharply higher on Wednesday, with multiple names posting substantial intraday gains. Metis TechBio-P (07666) jumped 13.65% to HK$17.65, while Joinn (06127) advanced 12.14% to HK$25.86. HBM Holdings-B (02142) climbed 9.76% to HK$13.92, and ASCLETIS-B (01672) rose 8.9% to HK$8.87. Zai Lab (09688) also gained 4.77% to HK$20.64.

The rally came as China's Ministry of Industry and Information Technology, along with nine other government departments, jointly released the 15th Five-Year Plan for the Development of the Pharmaceutical Industry. The plan outlines targets through 2030, including solidifying the nation's position among the global leaders in biomedical research and application, fully unleashing innovation-driven efficiency, achieving systemic breakthroughs in core technologies in key areas, and accelerating the industry's emergence as a new strategic pillar of the national economy. Specific goals include an average annual growth rate of over 20% for the innovative drug sector and the development of five or more products with global annual sales exceeding US$1 billion.

Adding to the momentum, a wave of catalysts has emerged recently in the AI-driven drug discovery space. Novo Nordisk announced a partnership with Anthropic, while GenScript revealed a collaboration with Eli Lilly. Additionally, ByteDance's AI-drug development platform has attracted fresh financing. Analysts at Zheshang Securities noted that high-frequency iterations will likely fuel a surge in short-term demand for validation services. However, they added that over the long term, rapid advancement could enhance platform capabilities and broaden applications. The firms that can continuously evolve their discovery platforms may become the core of the industry, and a "Claude moment" for the pharmaceutical sector may be on the horizon.